Abstract
I would like to respond to the paper of Paulzen et al. (2007), who report an enhancement of atomoxetine serum levels by co-administration of paroxetine. Atomoxetine, a noradrenaline and dopamine reuptake inhibitor, has also been developed for attention deficit …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The international journal of neuropsychopharmacology
Paper Title
Journal
Date
